Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Jianrong Wu"'
Autor:
Jing Wei, Jianrong Wu
Publikováno v:
Pharm Stat
A challenge arising in cancer immunotherapy trial design is the presence of a delayed treatment effect wherein the proportional hazard assumption no longer holds true. As a result, a traditional survival trial design based on the standard log-rank te
Autor:
Rachel C. Brennan, Barry L. Shulkin, Shenghua Mao, Alberto S. Pappo, Paul M. Sondel, M. Beth McCarville, Wayne L. Furman, Victor M. Santana, Wing Leung, Catherine Y.C. Ng, Paul R. Hutson, William E. Janssen, Aaron Shafer, Sara M. Federico, Michael M Meagher, Jianrong Wu, Jacquelyn A. Hank
Publikováno v:
Clin Cancer Res
Purpose: Anti-GD2 mAbs, acting via antibody-dependent cell-mediated cytotoxicity, may enhance the effects of chemotherapy. This pilot trial investigated a fixed dose of a unique anti-GD2 mAb, hu14.18K322A, combined with chemotherapy, cytokines, and h
Publikováno v:
Pharm Stat
Molecularly targeted, genomic-driven, and immunotherapy-based clinical trials continue to be advanced for the treatment of relapse or refractory cancer patients, where the growth modulation index (GMI) is often considered a primary endpoint of treatm
Autor:
Jianrong Wu
Publikováno v:
Pharmaceutical Statistics. 14:226-232
The current practice of designing single-arm phase II survival trials is limited under the exponential model. Trial design under the exponential model may not be appropriate when a portion of patients are cured. There is no literature available for d
Autor:
Daniel M. Green, M. Beth McCarville, Rachel C. Brennan, Mark A. Williams, Jeffrey S. Dome, Matthew J. Krasin, Rodrigo B. Interiano, Jianrong Wu, Noel M. Delos Santos, Kathleen Kieran, Shenghua Mao, Andrew M. Davidoff
Publikováno v:
Journal of pediatric surgery. 52(1)
The purpose of this study was to perform a comprehensive assessment of long-term renal function in patients treated at our institution for synchronous bilateral Wilms tumor (BWT) and to determine the optimal method for estimating glomerular filtratio
Autor:
Shuiying Hu, M. Beth McCarville, Lisa M. McGregor, Fariba Navid, Jianrong Wu, John C. Panetta, Wilburn E. Reddick, Demba Fofana, Wing Leung, Sharyn D. Baker, Wayne L. Furman, Victor M. Santana, David C. Turner, Sheri L. Spunt, Clinton F. Stewart, Andrew M. Davidoff, Catherine A. Billups
Publikováno v:
Clinical Cancer Research. 19:236-246
Purpose: To determine the maximum-tolerated dose (MTD), dose-limiting toxicities (DLT), pharmacokinetics, and pharmacodynamics of sorafenib, bevacizumab, and low-dose oral cyclophosphamide in children and young adults with recurrent/refractory solid
Autor:
Wayne L. Furman, Peter J. Houghton, Dana Hawkins, Victor M. Santana, Jianrong Wu, M. Beth McCarville, Valerie McPherson, Mihaela Onciu, Lisa M. McGregor, Sandy Kovach, Clinton F. Stewart, Andrew M. Davidoff, Catherine A. Billups
Publikováno v:
Investigational New Drugs. 30:1660-1670
Background Gefitinib potently inhibits neuroblastoma proliferation in vitro, and the gefitinib/irinotecan combination shows greater than additive activity against neuroblastoma xenografts. This Phase II pilot study estimated the rate of response to t
Autor:
Jianrong Wu
Publikováno v:
Journal of Biopharmaceutical Statistics. 20:954-964
The tumor growth inhibition T/C ratio is commonly used to quantify treatment effects in drug screening tumor xenograft experiments. The T/C ratio is converted to an antitumor activity rating using an arbitrary cutoff point and often without any forma
Autor:
Doralina L, Anghelescu, Jacob L, Goldberg, Lane G, Faughnan, Jianrong, Wu, Shenghua, Mao, Wayne L, Furman, Victor M, Santana, Fariba, Navid
Addition of anti-GD2 antibody ch14.18 to the treatment of neuroblastoma has improved outcomes. The most common side effect of ch14.18 is neuropathic pain, which may in part be complement-mediated. Hu14.18K322A is a humanized anti-GD2 antibody designe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::23c0daef6e01bd692ae99ad1d08a7af7
https://europepmc.org/articles/PMC4425626/
https://europepmc.org/articles/PMC4425626/
Autor:
Vickie Given, Thomas E. Merchant, Catherine A. Billups, Ibrahim Qaddoumi, Erin Sullivan, Carlos Rodriguez-Galindo, Barry L. Shulkin, Rachel C. Brennan, Tammy M. Free, Matthew W. Wilson, Jianrong Wu, Barrett G. Haik
Background There are no standardized diagnostic or treatment guidelines for patients with advanced unilateral retinoblastoma. Materials and methods Patients with advanced unilateral retinoblastoma were prospectively treated after enucleation using a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1914e98e0124d74990901e02c12051b1
https://europepmc.org/articles/PMC4108566/
https://europepmc.org/articles/PMC4108566/